Trial Profile
A Prospective, Randomised, Controlled, Open-label, Non-inferiority Trial to Compare the Efficacy of Standard of Care Combination Antiretroviral Therapy With a Simplified Dolutegravir Monotherapy in Patients With a Primary HIV-1 Infection Under Suppressive Early Standard of Care Antiretroviral Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Jun 2023
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms Early Simplified
- 20 Jun 2023 Results published in the Clinical Infectious Diseases
- 02 Jan 2019 Primary endpoint (Proportion of individuals with a viral failure [defined as 2 plasma viremia levels 50copies/ml at least two weeks apart] at week 48 or before.) has been met as per results published in the Clinical Infectious Diseases
- 02 Jan 2019 Results published in the Clinical Infectious Diseases